Squarepoint
CNCE

Squarepoint’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Squarepoint’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,265
Closed -$47K – 3621
2022
Q2 		$47K Buy
+11,265
New +$44.6K ﹤0.01% 2711
2021
Q4 		– Sell
-27,233
Closed -$89K – 3648
2021
Q3 		$89K Sell
27,233
-16,236
-37% -$56.9K ﹤0.01% 2692
2021
Q2 		$183K Buy
43,469
+5,557
+15% +$23.5K ﹤0.01% 2868
2021
Q1 		$189K Buy
+37,912
New +$306K ﹤0.01% 2716
2020
Q4 		– Sell
-20,393
Closed -$200K – 3374
2020
Q3 		$200K Buy
+20,393
New +$201K ﹤0.01% 2094
2020
Q2 		– Sell
-42,469
Closed -$375K – 2608
2020
Q1 		$375K Sell
42,469
-18,058
-30% -$178K 0.01% 1190
2019
Q4 		$558K Sell
60,527
-4,673
-7% -$33.1K ﹤0.01% 1710
2019
Q3 		$383K Buy
65,200
+44,104
+209% +$468K ﹤0.01% 1762
2019
Q2 		$253K Buy
21,096
+3,170
+18% +$34.1K ﹤0.01% 1998
2019
Q1 		$216K Buy
+17,926
New +$264K ﹤0.01% 1923
2018
Q4 		– Sell
-42,200
Closed -$626K – 2327
2018
Q3 		$626K Buy
42,200
+3,500
+9% +$55.1K 0.01% 1204
2018
Q2 		$651K Buy
38,700
+15,464
+67% +$300K 0.01% 1069
2018
Q1 		$532K Buy
23,236
+3,973
+21% +$88.4K 0.01% 1072
2017
Q4 		$498K Sell
19,263
-2,237
-10% -$45K 0.01% 1216
2017
Q3 		$317K Buy
21,500
+5,100
+31% +$74K 0.01% 1156
2017
Q2 		$229K Buy
16,400
+2,636
+19% +$38.9K ﹤0.01% 1253
2017
Q1 		$235K Sell
13,764
-21,561
-61% -$259K 0.01% 1208
2016
Q4 		$363K Buy
+35,325
New +$323K 0.01% 1028

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's CNCE Position: Q3 2022 in Review

Squarepoint sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2022, closing a stake of 11,265 shares — an estimated $47K sold.

Squarepoint first reported a position in CNCE in Q4 2016 and held it in 18 quarters. The position peaked at $651K in Q2 2018. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2022.

  • Squarepoint reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Squarepoint sold 11,265 Concert Pharmaceuticals, Inc. shares in Q3 2022, an estimated $47K.
  • Squarepoint first reported a position in Concert Pharmaceuticals, Inc. in Q4 2016 and held it in 18 quarters.
  • Squarepoint's Concert Pharmaceuticals, Inc. position peaked at $651K in Q2 2018.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.